Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial (OBSERB)
Primary Purpose
Breast Neoplasm Female, Lymphatic Metastasis
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Radiotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Breast Neoplasm Female focused on measuring Breast cancer, cN1, ycN0, Neoadjuvant cheotherapy, Sentinel Lymph Node, Radiotherapy
Eligibility Criteria
Inclusion Criteria:
- women aged > 20 years
- cT1-3N1M0, primary invasive
- initially confirmed ALN by fine needle aspiration cytology before neoadjuvant chemotherapy
- completion of neoadjuvant chemotherapy
- tumors negative for LN metastasis confirmed by imaging after neoadjuvant chemotherapy
Exclusion Criteria:
- synchronous distant metastases
- previous other malignancy
- bilateral breast cancer
- previous primary systemic therapy
- pregnancy or breastfeeding
- pre-operative radiological evidence of multiple involved or suspicious axillary nodes
- patient with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Sentinel lymph node biopsy
Adjuvant radiation without Sentinel lymph node biopsy
Arm Description
Perform conventional sentinel lymph biopsy
Perform radiotherapy instead of sentinel lymph node biopsy
Outcomes
Primary Outcome Measures
Disease-free survival
Disease free survival including breast, axilla and other organs from medical record
Secondary Outcome Measures
Local recurrence
Ipsilateral breast from medical record
Axillary recurrence
Ipsilateral axillary lymph nodes from medical record
distant recurrence
Other organs except ipsilateral breast and axillary lymph nodes from medical record
distant free survival
No disease on other organs except ipsilateral breast and axillary lymph nodes from medical record
Overall survival
Overall survival from medical record
Full Information
NCT ID
NCT04116125
First Posted
October 1, 2019
Last Updated
October 2, 2019
Sponsor
Kyungpook National University Chilgok Hospital
Collaborators
Korean Breast Cancer Study Group
1. Study Identification
Unique Protocol Identification Number
NCT04116125
Brief Title
Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial
Acronym
OBSERB
Official Title
A Randomized Trial of Sentinel Lymph Node Biopsy vs Radiotherapy Alone After Neoadjuvant Chemotherapy in Patients Undergoing Breast Conserving Surgery With cT1-3N1, ycN0 Breast Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2020 (Anticipated)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kyungpook National University Chilgok Hospital
Collaborators
Korean Breast Cancer Study Group
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The OBSERB study is a multi-center, non-blinded, pragmatic, parallel, randomized controlled trial in which patients with cT1-3N1 and ycN0 breast cancer.
Detailed Description
The OBSERB study aims to compare the oncologic outcomes of radiotherapy without sentinel lymph node biopsy versus sentinel lymph node biopsy for the management of breast cancer which showed the cN1 was conversed as ycN0 after neoadjuvant chemotherapy.
To verify whether, the radiotherapy without SLN can be applied, when the cN1 was conversed as ycN0 after neoadjuvant chemotherapy.
To verify whether, the additional treatment decision can be established based on only the biology of primary tumor without the pathologic information of axillary lymph nodes To verify whether, the patients' quality of life can be improved by a less invasive surgical procedure, when the cN1 was conversed as ycN0 after neoadjuvant chemotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasm Female, Lymphatic Metastasis
Keywords
Breast cancer, cN1, ycN0, Neoadjuvant cheotherapy, Sentinel Lymph Node, Radiotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1380 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sentinel lymph node biopsy
Arm Type
Placebo Comparator
Arm Description
Perform conventional sentinel lymph biopsy
Arm Title
Adjuvant radiation without Sentinel lymph node biopsy
Arm Type
Experimental
Arm Description
Perform radiotherapy instead of sentinel lymph node biopsy
Intervention Type
Procedure
Intervention Name(s)
Radiotherapy
Intervention Description
Adjuvant radiotherapy on axillary region
Primary Outcome Measure Information:
Title
Disease-free survival
Description
Disease free survival including breast, axilla and other organs from medical record
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Local recurrence
Description
Ipsilateral breast from medical record
Time Frame
5 years
Title
Axillary recurrence
Description
Ipsilateral axillary lymph nodes from medical record
Time Frame
5 years
Title
distant recurrence
Description
Other organs except ipsilateral breast and axillary lymph nodes from medical record
Time Frame
5 years
Title
distant free survival
Description
No disease on other organs except ipsilateral breast and axillary lymph nodes from medical record
Time Frame
5 years
Title
Overall survival
Description
Overall survival from medical record
Time Frame
5 years
Other Pre-specified Outcome Measures:
Title
Quality of life by questionnaire
Description
Pain, Discomfort, Numbness, Rotation of arm, Lymphedema of arm
Time Frame
5 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
women aged > 20 years
cT1-3N1M0, primary invasive
initially confirmed ALN by fine needle aspiration cytology before neoadjuvant chemotherapy
completion of neoadjuvant chemotherapy
tumors negative for LN metastasis confirmed by imaging after neoadjuvant chemotherapy
Exclusion Criteria:
synchronous distant metastases
previous other malignancy
bilateral breast cancer
previous primary systemic therapy
pregnancy or breastfeeding
pre-operative radiological evidence of multiple involved or suspicious axillary nodes
patient with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial
We'll reach out to this number within 24 hrs